RTP Mobile Logo

Friday, February 27, 2026, San Francisco, California, 6:00 PM – 7:30 PM Pacific Time (9:00 PM – 10:30 PM Eastern Time)

Second Opinion: Clinical Investigators Provide Perspectives on the Future Role of AKT Inhibition in the Management of Prostate Cancer

A CME Symposium Held Adjunct to the 2026 ASCO® Genitourinary Cancers Symposium

Register for in-person Register for webcast

Event Details

 

Program Schedule — Pacific Time
5:45 PM – 6:00 PM — Registration
6:00 PM – 7:30 PM — Educational Dinner Meeting

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

No registration fee is charged for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Professor Karim Fizazi, MD, PhD
Head of Service and Full Professor
Institut Gustave Roussy
University of Paris Saclay
Villejuif, France

Daniel George, MD
Eleanor Easley Distinguished Chair
Professor of Medicine, Surgery and Urology
Duke University School of Medicine
ACS Research Professor
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina

Moderator
Elisabeth I Heath, MD
Chair, Department of Oncology
Mayo Clinic
Rochester, Minnesota



This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Agenda

Program Schedule — Pacific Time
5:45 PM – 6:00 PM — Registration
6:00 PM – 7:30 PM — Educational Dinner Meeting

MODULE 1: Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George

  • Validated molecular biomarkers to aid in risk stratification and/or clinical decision-making in prostate cancer; current guideline-recommended approaches to biomarker evaluation
  • Frequency of PTEN deficiency in patients with prostate cancer; role in prostate tumor formation and progression
  • Clinicopathological features and long-term outcomes associated with PTEN deficiency in patients with prostate cancer
  • Optimal timing of and approach to PTEN assessment; advantages and disadvantages of available testing platforms
  • Potential implications for biomarker evaluation of recently presented clinical trial findings with capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC)

MODULE 2: Emerging Role of AKT Inhibition in Therapy for mHSPC — Prof Fizazi

  • Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer; rationale for benefit in patients with PTEN-deficient disease
  • Outcomes noted from the Phase III IPATential150 study of ipatasertib in combination with abiraterone/prednisolone for metastatic castration-resistant prostate cancer; practical issues with ipatasertib and decision to discontinue the study
  • Pharmacologic similarities and differences between ipatasertib and capivasertib; implications for efficacy and tolerability
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/androgen deprivation therapy (ADT) for patients with de novo mHSPC and PTEN deficiency
  • Published results from the CAPItello-281 trial demonstrating a radiographic progression-free survival advantage with the addition of capivasertib to abiraterone/ADT
  • Potential integration of capivasertib/abiraterone/ADT into treatment algorithms; optimal use in light of other currently available regimens

MODULE 3: Tolerability and Other Practical Considerations with Capivasertib — Dr Heath

  • Spectrum of toxicities associated with capivasertib; tolerability of this agent in combination with abiraterone/ADT
  • Recommended management strategies for diarrhea and other gastrointestinal disorders in patients receiving capivasertib
  • Incidence of hyperglycemia in patients receiving capivasertib; appropriate glucose monitoring and interventions for elevated blood glucose levels
  • Optimal mitigation and management of cutaneous adverse reactions associated with capivasertib
  • Appropriate monitoring of complete blood counts in patients receiving capivasertib; recommended dose modifications in response to cytopenias
  • Role of interdisciplinary coordination in the management of capivasertib-related adverse events

CE Information

Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the incidence and clinical relevance of PTEN deficiency in prostate cancer, and develop an understanding of the optimal method to assess PTEN status in patients.
  • Assess the clinical and biological factors in the selection of therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in order to optimally personalize treatment recommendations.
  • Evaluate available Phase III data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency, and consider the potential role of this form of treatment.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with AKT inhibitors in preparation for their potential availability for patients with prostate cancer.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Fizazi — Institutional Honoraria: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc. Dr George — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Candel Therapeutics, Convergent Therapeutics Inc, Dendreon Pharmaceuticals LLC, Johnson & Johnson, Merck, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Johnson & Johnson, Novartis, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc, pharmaand GmbH; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Stock Options/Stock — Public Companies: Bristol Myers Squibb, Pfizer Inc; Nonrelevant Financial Relationships: IDEOlogy Health, MJH Life Sciences, Onclive, Targeted Oncology.

CONSULTING CLINICAL INVESTIGATORS — Neeraj Agarwal, MD, FASCO has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Rana R McKay, MD, FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.

MODERATOR

Dr Heath — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Gilead Sciences Inc, Novartis, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (to Institution): Novartis; Contracted Research (Research Support to Institution): Altor Bioscience Corporation, Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Clarity Pharmaceuticals, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Janux Therapeutics, Johnson & Johnson, MacroGenics Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Regeneron Pharmaceuticals Inc, Seagen Inc, Xencor; Nonrelevant Financial Relationships (to Institution): Calibr-Skaggs Institute for Innovative Medicines.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Location

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2026 ASCO Genitourinary Cancers Symposium is taking place.

 

Registration

This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

No registration fee is charged for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

NOTICE
Registration for this event is independent of registration for the 2026 ASCO Genitourinary Cancers Symposium.

IN-PERSON Registration
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. Seats are still available for this session. Our onsite registration desk will be open at 5:30 PM PT on Friday, February 27th. If you are interested in attending, please visit our registration desk outside the Golden Gate Ballroom — Salon A (B2 Level) — at the San Francisco Marriott Marquis hotel, 780 Mission Street, within walking distance (2 blocks) of the Moscone Convention Center. Please note: Seats will be offered on a first come, first served basis after prioritizing for clinicians in practice, and onsite registration does not guarantee participation in the meal service.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE
Registration for this event is independent of registration for the 2026 ASCO Genitourinary Cancers Symposium.
WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.